Abstract

Aim: The aim of this investigation was to identify which part of a dose mesalazine is acetylated by enzymes in the gut wall during the absorption process, and which part by the liver enzymes after absorption. Method: This study was based on data from four bioequivalence studies of different formulations of tablets (gastro-resistant single dose 500 mg (n = 24) and prolonged-release tablets (single dose 1000 mg, n = 18; multiple dose 1000 mg t.i.d. six days n = 28), suppositories (single 500 mg dose, n = 24) and a study with two i.v. administrations of 100 and 250 mg mesalazine (n = 6). In total, 200 administrations were carried out and plasma concentration-time curves obtained and analyzed. There was a large variability in the absorption of mesalazine for all formulations. The plasma concentration-time curves of parent drug and metabolite acetylmesalazine run nearly parallel, independent of the formulation and the dose. Plasma and urine mesalazine and acetylmesalazine concentrations were determined according to validated methods using HPLC analysis with coulometric or mass-spectrometric detection. Results: As a result of the large variations in release and absorption of mesalazine in the pharmaceutical formulations and administrations, it was possible to demonstrate that acetylation occurs in the gut wall and in the liver. By comparing oral and rectal data to intravenous data, it was possible to indicate where (and to what extent) acetylation occurs in the gut wall, in the liver, or both. Rectal administration of a mesalazine suppository and intravenous administration results in hepatic acetylation. Oral administrations of mesalazine results in both gut wall and hepatic acetylation. Acetylation by the gut wall amounts to 30% of the dose for gastro-resistant tablets and to 40% of the dose for prolonged-release tablets.

Author Details

Authors

• T.B. Vree¹
• E. Dammers²
• P.S. Exler³
• F. Sörgel⁴
• S. Bondesen⁵
• R.A.A. Maes⁶

Departments

• ¹ Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud,
• ² DADA Consultancy, Nijmegen,
• ³ Disphar International, Hengelo (Gld), The Netherlands,
• ⁴ Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany,
• ⁵ Frederiksberg Hospital, Copenhagen, Denmark, and
• ⁶ Department of Human Toxicology, University of Utrecht, Utrecht, The Netherlands

Address

Dr. T.B. Vree; Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, P.O. Box 9101, NL-6500 HB Nijmegen, The Netherlands

Log in for Subscribers

Citation